Fever in Anti-GBM Disease
Yes, fever is a common presenting symptom in anti-GBM disease, occurring in approximately two-thirds of patients, and is most often associated with respiratory tract infections that may trigger or accompany the autoimmune process. 1
Clinical Significance of Fever
Fever presents in 67.1% of patients with anti-GBM disease either prior to admission or within 48 hours of hospitalization. 1 This is not merely an incidental finding—patients presenting with fever demonstrate more severe disease manifestations and worse outcomes:
- Higher serum anti-GBM antibody levels (154.9 vs. 106.0 IU/mL in non-febrile patients) 1
- More severe renal dysfunction (serum creatinine 733.4 vs. 580.6 μmol/L) 1
- More aggressive glomerular injury (87.0% vs. 67.4% crescents on biopsy) 1
- Higher progression to end-stage renal disease (80.9% vs. 60.9%) 1
Infection as the Primary Cause
Among febrile patients with anti-GBM disease, 78.7% have documented infections, predominantly affecting the respiratory system. 1 The infection distribution includes:
Identified pathogens include Candida albicans, Escherichia coli, Acinetobacter baumannii, Enterococcus faecalis, Klebsiella pneumoniae, hemolytic staphylococci, Pseudomonas aeruginosa, and Citrobacter braakii. 1
Critical Clinical Pitfall
The presence of fever and infection creates a diagnostic and therapeutic dilemma: The KDIGO guidelines emphasize that infection must be excluded with as much certainty as possible before initiating significant immunosuppression in rapidly progressive glomerulonephritis. 2 However, in anti-GBM disease, the infection may be both a trigger and a concurrent finding, making this distinction challenging.
Do not delay immunosuppressive therapy while pursuing exhaustive infection workup if clinical presentation is compatible with anti-GBM disease and antibodies are positive. 2 The rapidly progressive nature of anti-GBM disease means that waiting for complete infection clearance can result in irreversible kidney damage. 3, 4
ANCA Co-positivity Consideration
Only 16.0% of febrile anti-GBM patients have concurrent ANCA positivity (specifically MPO-ANCA), which is comparable to non-febrile patients (17.4%). 1 This indicates that fever in anti-GBM disease is primarily infection-related rather than due to ANCA-associated vasculitis overlap.
Pathogenic Role of Infections
Infections, particularly respiratory tract infections, are recognized as potential triggers for anti-GBM disease through mechanisms including direct damage to basement membranes and epitope mimicry with microbial peptides. 4, 5 Environmental factors and infections may trigger the autoimmune response in genetically susceptible individuals. 6